InsidersTradesSigma
Total declarations
Company
▲ Purchases (22 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
22
Disclosed sells
0
T+90 hit rate
7%
T+90 mean return
-25.6%
Across 14 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Equels Thomas K., Chairman & CEO. Officer active across 1 company, notably AIM ImmunoTech Inc.. Aggregated, 34 disclosures have been recorded. Breakdown: 22 buys · 0 sell. Total volume traded: €275k. Activity tracked since 16 July 2021. The latest transaction was disclosed on 12 March 2026 (C). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Equels Thomas K.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations34 total
25,000 shares0Common stockSEC:0001493152-26-010334:0
107 shares@ US$7.6970.1% of flowCommon StockSEC:0001641172-25-015207:0
Canonical exit: 11 Sept 2025 (T+90)
103 shares@ US$8.700.1% of flowCommon StockSEC:0001641172-25-015005:0
Canonical exit: 10 Sept 2025 (T+90)
1,968,504 shares@ US$0.02547.2% of flowCommon StockSEC:0001641172-25-005861:0
Canonical exit: 10 Jul 2025 (T+90)
41,000 shares@ US$0.0630.4% of flowCommon StockSEC:0001641172-25-002977:0
Canonical exit: 3 Jul 2025 (T+90)
50,000 shares@ US$0.13461.0% of flowCommon StockSEC:0001493152-25-009338:0
Canonical exit: 3 Jun 2025 (T+90)
44,000 shares@ US$0.1150.8% of flowCommon StockSEC:0001493152-25-009164:0
Canonical exit: 2 Jun 2025 (T+90)
83,334 shares@ US$0.121.5% of flowCommon StockSEC:0001493152-25-009003:0
Canonical exit: 2 Jun 2025 (T+90)
20,000 shares@ US$0.2120.7% of flowCommon StockSEC:0001493152-25-003058:0
Canonical exit: 19 Feb 2025 (T+90)
22,727 shares@ US$0.2060.7% of flowCommon StockSEC:0001493152-24-050757:0
Canonical exit: 18 Mar 2025 (T+90)
85,000 shares@ US$0.1992.6% of flowCommon StockSEC:0001493152-24-047094:0
Canonical exit: 18 Feb 2025 (T+90)
60,110 shares@ US$0.1831.7% of flowCommon StockSEC:0001493152-24-046952:0
Canonical exit: 18 Feb 2025 (T+90)
5,000 shares@ US$0.3030.2% of flowCommon StockSEC:0001493152-24-036837:0
Canonical exit: 15 Dec 2024 (T+90)
20,000 shares@ US$0.3080.9% of flowCommon StockSEC:0001493152-24-036364:0
Canonical exit: 12 Dec 2024 (T+90)
312,500 shares@ US$0.3214.7% of flowCommon StockSEC:0001493152-24-036076:0
377,358 shares@ US$0.26514.8% of flowCommon StockSEC:0001493152-24-031414:0
61,729 shares@ US$0.4053.8% of flowCommon StockSEC:0001493152-24-018030:0
Canonical exit: 4 Aug 2024 (T+90)
75,758 shares@ US$0.333.7% of flowCommon StockSEC:0001493152-24-010267:0
Canonical exit: 13 Jun 2024 (T+90)
33,861 shares@ US$0.4432.2% of flowCommon StockSEC:0001493152-23-042743:0
Canonical exit: 25 Feb 2024 (T+90)
22,676 shares@ US$0.4413.6% of flowCommon StockSEC:0001493152-23-034802:0
Canonical exit: 28 Dec 2023 (T+90)
8,222 shares@ US$0.6690.8% of flowCommon StockSEC:0001493152-23-030180:0
Canonical exit: 23 Nov 2023 (T+90)
14,993 shares@ US$0.6671.5% of flowCommon StockSEC:0001493152-23-030077:0
Canonical exit: 22 Nov 2023 (T+90)
16,950 shares@ US$0.591.4% of flowCommon StockSEC:0001493152-23-024767:0
Canonical exit: 15 Oct 2023 (T+90)
161,291 shares@ US$0.317.6% of flowCommon StockSEC:0001493152-23-000211:0
Canonical exit: 3 Apr 2023 (T+90)
32,895 shares@ US$0.764.0% of flowCommon StockSEC:0001450324-22-000004:0
25 of 34 declarations
About Equels Thomas K.
EQUELS THOMAS K. is President-CEO and appears in 34 filings in total. Across the 34 filings in the recent sample, they relate to AIM ImmunoTech Inc., with EUR 275496 of purchases and EUR 0 of sales, between 2021-07-16 and 2026-03-16.
